Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBL 202

Next Previous
Drug Profile

IBL 202

Alternative Names: IBL-202

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spanish National Cancer Research Centre
  • Developer Inflection Biosciences; Kolling Institute of Medical Research; Multiple Myeloma Research Foundation; University of Sydney; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Head and neck cancer; Multiple myeloma; T-cell lymphoma

Most Recent Events

  • 06 Apr 2025 Preclinical trials in T-cell lymphoma in Ireland (PO)
  • 06 Apr 2025 Pharmacodynamics data from a preclinical studies in T-cell lymphoma released by Inflection Biosciences
  • 28 Nov 2022 Preclinical trials in Acute myeloid leukaemia in Ireland (PO) (Inflection Biosciences pipeline, November 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top